Deutsche Bank AG Buys 319,709 Shares of Zoetis Inc. $ZTS

Deutsche Bank AG boosted its stake in Zoetis Inc. (NYSE:ZTS) by 5.8% during the 2nd quarter, Holdings Channel reports. The firm owned 5,851,737 shares of the company’s stock after buying an additional 319,709 shares during the quarter. Deutsche Bank AG’s holdings in Zoetis were worth $420,506,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Zoetis during the second quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis in the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis in the first quarter worth about $28,000. Root Financial Partners LLC boosted its stake in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new position in Zoetis during the fourth quarter valued at approximately $32,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research reports. HSBC reduced their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. William Blair reissued a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. UBS Group reduced their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Citigroup decreased their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Finally, BNP Paribas Exane lowered their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $109.62.

Zoetis Price Performance

ZTS opened at $72.71 on Tuesday. The business has a fifty day moving average of $76.17 and a 200 day moving average of $98.47. The stock has a market cap of $30.05 billion, a P/E ratio of 11.98, a PEG ratio of 1.28 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 52-week low of $71.00 and a 52-week high of $160.48.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the firm posted $1.76 earnings per share. The business’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 34.93%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.